 | • レポートコード：B-MOR-040824 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、抗真菌薬の世界市場について調べ、抗真菌薬の世界規模、市場動向、市場環境、薬物タイプ別（エキノカンジン、アゾール、ポリエン、アリルアミン、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・抗真菌薬の世界市場インサイト ・抗真菌薬の世界市場環境 ・抗真菌薬の世界市場動向 ・抗真菌薬の世界市場規模 ・抗真菌薬の世界市場規模：薬物タイプ別（エキノカンジン、アゾール、ポリエン、アリルアミン、その他） ・抗真菌薬の世界市場：地域別市場規模・分析 ・抗真菌薬の北米市場規模・予測 ・抗真菌薬のアメリカ市場規模・予測 ・抗真菌薬のヨーロッパ市場規模・予測 ・抗真菌薬のアジア市場規模・予測 ・抗真菌薬の日本市場規模・予測 ・抗真菌薬の中国市場規模・予測 ・抗真菌薬のインド市場規模・予測 ・抗真菌薬の韓国市場規模・予測 ・関連企業情報・競争状況 |
Antifungal drugs are used to cure fungal infections, which occur due to unclean, unhygienic, and damp environment. Fungal infections are caused by microscopic organisms invading epithelial tissue. Systemic fungal infections are usually caused by the indigestion or inhalation of fungus spores and cause fungal pneumonia, and opportunistic fungus causes diseases, such as candidiasis, meningitis, mucormycosis, etc. The global anti-fungal drugs market is expected to register a CAGR of 3.7% during the forecast period, 2018 to 2023.
Increasing Number of Anti-fungal Drugs as Over-The-Counter (OTC)
With rising popularity of over-the-counter (OTC) drugs, many patients prefer them to obtaining a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, as these infections can be treated by OTC drugs, owing to their ease of availability.
Increasing awareness about myriad fungal infections and increasing government and corporate funding are some other drivers of the market.
Presence of Generics and Government Regulations in the Pharmaceutical Industry
Although there is an increase in the sales of anti-fungal generic drugs, the market value of these drugs has decreased, as the price of generics is almost 20 to 50% of the branded drugs. To meet the market value, the sales of generics must be increased by at least four times to that of branded drugs. Even with the increasing volume of generic anti-fungal drug sales, the overall market value of anti-fungal drugs has reduced.
Additionally, high penetration of conventional drugs used for treatment and allergic reaction to some types of anti-fungal drugs are also restraining the market growth.
North America to Dominate the Market
The global anti-fungal drugs market is segmented by drug type, therapeutic indication, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
North America dominates the market due to increasing awareness of fungal infections with the growing incidence of antifungal infections and increasing government and corporate funding in the industry.
Major Players: ABBOTT LABORATORIES, PFIZER, GLAXOSMITHKLINE, BAYER HEALTHCARE, NOVARTIS, SANOFI-AVENTIS, MERCK & CO., KRAMER LABORATORIES, ENZON PHARMACEUTICALS, GILEAD amongst others.
Reasons to Purchase this Report
• Market analysis for the global anti-fungal drugs market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porter’s Five Force Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Degree of Competition
5.3.4 Threat of Substitution
5.3.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Number of Antifungal Drugs As Over-The-Counter (OTC)
6.1.2 Increasing Awareness about the Myriad Fungal Infections
6.1.3 Increasing Government and Corporate Funding
6.1.4 Rise in Number of Immune-Compromised Aged Population
6.1.5 Increasing Population Coming in Contact with Resistant Fungal Strains and Infections
6.2 Market Restraints
6.2.1 High Penetration of Conventional Drugs used for Treatment
6.2.2 Presence of Generics and Government Regulations in Pharmaceutical Industry
6.2.3 Allergic Reaction to Some Types of Anti-Fungal Drugs
6.3 Opportunities
6.3.1 Introduction of New Anti-Fungal Drugs
6.4 Challenges
6.4.1 Increasing Resistance to Anti-Fungal Drugs
7.Market Segmentation
7.1 By Drug Type
7.1.1 Echinocandins
7.1.1.1 Pneumocandins
7.1.1.2 Caspofungin
7.1.1.3 Micafungin
7.1.1.4 Anidulafungin
7.1.1.5 Others
7.1.2 Azoles
7.1.2.1 Voricanazole
7.1.2.2 Imidazoles
7.1.2.3 Triazoles
7.1.2.4 Thiazoles
7.1.2.5 Others
7.1.3 Polyenes
7.1.3.1 Amphotericin B
7.1.3.2 Candicidin
7.1.3.3 Hamycin
7.1.3.4 Natamycin
7.1.3.5 Others
7.1.4 Allylamines
7.1.4.1 Lamisil
7.1.4.2 Terbinafine
7.1.4.3 Others
7.1.5 Others
7.1.5.1 Benzoic Acid
7.1.5.2 Ciclopirox
7.1.5.3 Greisiofulvin
7.1.5.4 By Therapeutic Indication
7.1.5.5 Aspergillosis
7.1.5.6 Dermatophytosis
7.1.5.7 Candidiasis
7.2 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 US
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 Germany
7.3.2.2 UK
7.3.2.3 France
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe (RoE)
7.3.3 Asia Pacific
7.3.3.1 Japan
7.3.3.2 China
7.3.3.3 India
7.3.3.4 South Korea
7.3.3.5 Australia
7.3.3.6 Rest of Asia Pacific
7.3.4 The Middle East & Africa
7.3.4.1 GCC Countries
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8.Competitive Landscape
8.1 Mergers & Acquisitions
8.2 Agreements, Collaborations & Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Pfizer
9.3 GlaxoSmithKline
9.4 Bayer Healthcare
9.5 Novartis
9.6 Sanofi-Aventis
9.7 Merck & Co.
9.8 Kramer Laboratories
9.9 Enzon Pharmaceuticals
9.10 Gilead
10. Future of the Market